G6PD and acne: A PGx study has been conducted in patients diagnosed with acne vulgaris, treated with topical dapsone and with deficient G6PD, showing that it does not represent a clinically significant risk of hemolysis or anemia; however, the FDA also recommends avoiding the administration of this drug even topically in patients with G6PD deficiencies.